CPRX
NASDAQ · Biotechnology
Catalyst Pharmaceuticals Inc
$31.15
-0.02 (-0.05%)
Financial Highlights (FY 2026)
Revenue
566.44M
Net Income
206.12M
Gross Margin
85.2%
Profit Margin
36.4%
Rev Growth
+40.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 85.2% | 85.2% | 52.9% | 52.9% |
| Operating Margin | 43.8% | 39.4% | -3.8% | -3.6% |
| Profit Margin | 36.4% | 34.6% | -4.1% | -3.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 566.44M | 404.31M | 680.16M | 572.88M |
| Gross Profit | 482.55M | 344.43M | 359.61M | 302.89M |
| Operating Income | 247.93M | 159.27M | -25,547,896 | -20,889,894 |
| Net Income | 206.12M | 132.41M | -27,885,830 | -22,377,250 |
| Gross Margin | 85.2% | 85.2% | 52.9% | 52.9% |
| Operating Margin | 43.8% | 39.4% | -3.8% | -3.6% |
| Profit Margin | 36.4% | 34.6% | -4.1% | -3.9% |
| Rev Growth | +40.1% | +40.1% | +20.9% | +0.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 189.84M | 198.18M |
| Total Equity | — | — | 943.57M | 951.70M |
| D/E Ratio | — | — | 0.20 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 284.90M | 193.19M | -33,860,903 | -30,836,411 |
| Free Cash Flow | — | — | -33,852,425 | -29,658,150 |